

# Victor Mangas Sanjuan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4018134/publications.pdf>

Version: 2024-02-01

56  
papers

797  
citations

516215

16  
h-index

552369

26  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1268  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5825-5841.	2.9	88
2	Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. <i>Pharmaceutics</i> , 2019, 11, 365.	2.0	86
3	In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. <i>Molecular Informatics</i> , 2011, 30, 376-385.	1.4	76
4	<i>In vitro</i> – <i>in vivo</i> correlations: general concepts, methodologies and regulatory applications. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 1935-1947.	0.9	36
5	Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 71, 21-32.	0.3	31
6	Ion-pair strategy for enabling amifostine oral absorption: Rat <i>in situ</i> and <i>in vivo</i> experiments. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 499-504.	1.9	28
7	Semimechanistic Cell-Cycle Type-Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 55-64.	1.3	26
8	Investigating the Discriminatory Power of BCS-Biowaiver <i>In Vitro</i> Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. <i>Molecular Pharmaceutics</i> , 2015, 12, 3167-3174.	2.3	26
9	Drug penetration across the blood–brain barrier: an overview. <i>Therapeutic Delivery</i> , 2010, 1, 535-562.	1.2	24
10	A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. <i>European Journal of Medicinal Chemistry</i> , 2014, 83, 366-373.	2.6	22
11	Innovative <i>In Vitro</i> Method To Predict Rate and Extent of Drug Delivery to the Brain across the Blood–Brain Barrier. <i>Molecular Pharmaceutics</i> , 2013, 10, 3822-3831.	2.3	19
12	Modified Nonsink Equation for Permeability Estimation in Cell Monolayers: Comparison with Standard Methods. <i>Molecular Pharmaceutics</i> , 2014, 11, 1403-1414.	2.3	18
13	Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles. <i>AAPS Journal</i> , 2016, 18, 1550-1561.	2.2	18
14	Commentary on the MID3 Good Practices Paper. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 416-417.	1.3	18
15	Semisynthesis, Cytotoxic Activity, and Oral Availability of New Lipophilic 9-Substituted Camptothecin Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 651-655.	1.3	17
16	Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. <i>British Journal of Pharmacology</i> , 2015, 172, 829-840.	2.7	17
17	Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. <i>Pharmaceutics</i> , 2019, 11, 503.	2.0	17
18	<i>In vitro</i> – <i>in situ</i> permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2012, 37, 65-75.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Drug gastrointestinal absorption in rat: Strain and gender differences. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 78, 198-203.	1.9	15
20	Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. <i>Pharmaceutics</i> , 2021, 13, 935.	2.0	14
21	IVVC approach based on carbamazepine bioequivalence studies combination. <i>Die Pharmazie</i> , 2017, 72, 449-455.	0.3	12
22	Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets. <i>Molecular Pharmaceutics</i> , 2015, 12, 3194-3201.	2.3	11
23	Comparison of free software platforms for the calculation of the 90% confidence interval of f2 similarity factor by bootstrap analysis. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 146, 105259.	1.9	11
24	Importance and applications of cell- and tissue-based in vitro models for drug permeability screening in early stages of drug development. , 2016, , 3-29.		10
25	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 96-104.	1.3	9
26	Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. <i>Pharmaceutics</i> , 2021, 13, 709.	2.0	9
27	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1016.	2.0	9
28	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. <i>Pharmaceutics</i> , 2022, 14, 654.	2.0	9
29	Population pharmacokinetic model of lithium and drug compliance assessment. <i>European Neuropsychopharmacology</i> , 2016, 26, 1868-1876.	0.3	8
30	Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms. <i>Pharmaceutics</i> , 2020, 12, 1159.	2.0	8
31	Intestinal Permeability of Î²-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 795-806.	0.6	7
32	Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 300-308.	0.7	7
33	Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice. <i>Pharmaceutics</i> , 2020, 12, 975.	2.0	7
34	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. <i>Pharmaceutics</i> , 2022, 14, 1010.	2.0	7
35	Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 74, 86-94.	1.9	6
36	Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its Oâ€œdemethyl metabolite on pupil diameter and nociception in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 92-107.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Enhancing Oral Absorption of $\hat{f}^2$ -Lapachone: Progress Till Date. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 1-10.	0.6	6
38	A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokinetic model. Computer Methods and Programs in Biomedicine, 2020, 189, 105322.	2.6	6
39	Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. British Journal of Clinical Pharmacology, 2021, 87, 905-915.	1.1	6
40	Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. Xenobiotica, 2013, 43, 745-754.	0.5	5
41	Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. European Journal of Pharmaceutical Sciences, 2018, 117, 193-203.	1.9	5
42	Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat. Drug Metabolism and Disposition, 2017, 45, 152-159.	1.7	4
43	Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics, 2020, 12, 1226.	2.0	4
44	Estimators and confidence intervals of $\langle \text{mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.svg"} \rangle \langle \text{mml:msub} \rangle \langle \text{mml:mi} \rangle f \langle \text{mml:mi} \rangle \langle \text{mml:mn} \rangle 2 \langle \text{mml:mn} \rangle \langle \text{mml:msub} \rangle \langle \text{mml:math} \rangle$ using bootstrap methodology for the comparison of dissolution profiles. Computer Methods and Programs in Biomedicine, 2021, 212, 106449.	2.6	3
45	Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. European Journal of Pharmaceutical Sciences, 2015, 73, 57-63.	1.9	2
46	Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation. European Journal of Pharmaceutical Sciences, 2018, 119, 200-207.	1.9	2
47	EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma. Oncologist, 2020, 25, 1067-1074.	1.9	2
48	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. Cancers, 2021, 13, 5049.	1.7	2
49	Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics. European Journal of Pharmaceutical Sciences, 2022, 174, 106198.	1.9	1
50	Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior $\hat{A}$ ®EPOCIM in New Zealand rabbits. European Journal of Pharmaceutical Sciences, 2018, 120, 123-132.	1.9	0
51	Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. Pharmaceutics, 2020, 12, 1147.	2.0	0
52	ARE SHORT AND TEST QUESTIONS ADEQUATELY BALANCED?. , 2017, , .		0
53	BEST PREDICTOR OF FINAL MARK. , 2017, , .		0
54	STUDY OF EXPECTATIONS, LEARNING ABILITY AND SATISFACTION THROUGH THE ERASMUS + PROGRAM. EDULEARN Proceedings, 2020, , .	0.0	0

#	ARTICLE	IF	CITATIONS
55	DEVELOPMENT OF AN OPEN SOURCE PLATFORMS FOR IMPROVING THE LEARNING PROCESS IN PHARMACY. , 2020, , .		0
56	Quantitative assessment of the exposureâ€“efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy. British Journal of Clinical Pharmacology, 2022, 88, 2727-2737.	1.1	0